title: BNIP3 heterodimerizes with Bcl-2/Bcl-X(L) and induces cell death independent of a Bcl-2 homology 3 (BH3) domain at both mitochondrial and nonmitochondrial sites.
abstract: BNIP3 (formerly NIP3) is a pro-apoptotic, mitochondrial protein classified in the Bcl-2 family based on limited sequence homology to the Bcl-2 homology 3 (BH3) domain and COOH-terminal transmembrane (TM) domain. BNIP3 expressed in yeast and mammalian cells interacts with survival promoting proteins Bcl-2, Bcl-X(L), and CED-9. Typically, the BH3 domain of pro-apoptotic Bcl-2 homologues mediates Bcl-2/Bcl-X(L) heterodimerization and confers pro-apoptotic activity. Deletion mapping of BNIP3 excluded its BH3-like domain and identified the NH(2) terminus (residues 1-49) and TM domain as critical for Bcl-2 heterodimerization, and either region was sufficient for Bcl-X(L) interaction. Additionally, the removal of the BH3-like domain in BNIP3 did not diminish its killing activity. The TM domain of BNIP3 is critical for homodimerization, pro-apoptotic function, and mitochondrial targeting. Several TM domain mutants were found to disrupt SDS-resistant BNIP3 homodimerization but did not interfere with its killing activity or mitochondrial localization. Substitution of the BNIP3 TM domain with that of cytochrome b(5) directed protein expression to nonmitochondrial sites and still promoted apoptosis and heterodimerization with Bcl-2 and Bcl-X(L). We propose that BNIP3 represents a subfamily of Bcl-2-related proteins that functions without a typical BH3 domain to regulate apoptosis from both mitochondrial and nonmitochondrial sites by selective Bcl-2/Bcl-X(L) interactions.
authors.affiliation: Manitoba Institute of Cell Biology, University of Manitoba, Winnipeg, Manitoba R3E 0V9, Canada.
authors.forename: R
authors.initials: R
authors.lastname: Ray
authors.forename: G
authors.initials: G
authors.lastname: Chen
authors.forename: C
authors.initials: C
authors.lastname: Vande Velde
authors.forename: J
authors.initials: J
authors.lastname: Cizeau
authors.forename: J H
authors.initials: JH
authors.lastname: Park
authors.forename: J C
authors.initials: JC
authors.lastname: Reed
authors.forename: R D
authors.initials: RD
authors.lastname: Gietz
authors.forename: A H
authors.initials: AH
authors.lastname: Greenberg
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D000906:Antibodies; D017209:Apoptosis; D019281:Dimerization; D005347:Fibroblasts; D006801:Humans; D007700:Kinetics; D008565:Membrane Proteins / Q000737:chemistry / Q000378:metabolism*; D008928:Mitochondria / Q000378:metabolism* / Q000648:ultrastructure; D008969:Molecular Sequence Data; D055503:Protein Multimerization; D011518:Proto-Oncogene Proteins; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000737:chemistry / Q000378:metabolism*; D051381:Rats; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis / Q000737:chemistry / Q000378:metabolism; D025521:Tumor Suppressor Proteins; D051020:bcl-X Protein; D001616:beta-Galactosidase / Q000378:metabolism
chemical_list: D000906:Antibodies; C494811:BCL2L1 protein, human; C090121:BNIP3 protein, human; C116838:BNIP3L protein, human; C494813:Bcl2l1 protein, rat; D008565:Membrane Proteins; D011518:Proto-Oncogene Proteins; D019253:Proto-Oncogene Proteins c-bcl-2; D011993:Recombinant Fusion Proteins; D025521:Tumor Suppressor Proteins; D051020:bcl-X Protein; D001616:beta-Galactosidase